Zacks Investment Research upgraded shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) from a sell rating to a buy rating in a report published on Tuesday morning, Zacks.com reports. The firm currently has $5.25 target price on the stock.
According to Zacks, “Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel, transformative medicines for neurological diseases. Longboard Pharmaceuticals Inc. is based in SAN DIEGO. “
Other analysts have also issued reports about the stock. HC Wainwright initiated coverage on shares of Longboard Pharmaceuticals in a research note on Wednesday, April 27th. They issued a buy rating for the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Longboard Pharmaceuticals in a research note on Friday, April 1st. Finally, Wedbush initiated coverage on shares of Longboard Pharmaceuticals in a research note on Monday, February 14th. They issued an outperform rating and a $14.00 price objective for the company.
Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.04). Research analysts forecast that Longboard Pharmaceuticals will post -2.46 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in LBPH. TD Asset Management Inc. lifted its position in shares of Longboard Pharmaceuticals by 237.1% during the third quarter. TD Asset Management Inc. now owns 57,275 shares of the company’s stock valued at $510,000 after buying an additional 40,282 shares during the last quarter. Geode Capital Management LLC purchased a new stake in shares of Longboard Pharmaceuticals during the third quarter valued at about $135,000. Veritable L.P. purchased a new stake in shares of Longboard Pharmaceuticals during the third quarter valued at about $182,000. Bank of America Corp DE lifted its position in shares of Longboard Pharmaceuticals by 46.4% during the fourth quarter. Bank of America Corp DE now owns 23,525 shares of the company’s stock valued at $115,000 after buying an additional 7,453 shares during the last quarter. Finally, Citigroup Inc. purchased a new stake in shares of Longboard Pharmaceuticals during the fourth quarter valued at about $968,000.
Longboard Pharmaceuticals Company Profile (Get Rating)
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
- Get a free copy of the StockNews.com research report on Longboard Pharmaceuticals (LBPH)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Longboard Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.